Cardiff Lexington Corp (CDIX): Entry into a Material Definitive Agreement

Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 cardiff_ex1001.htm COMMON STOCK PURCHASE AGREEMENT, DATED JUNE 5, 2026 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of June 5, 2026 (this “ Agreement ”), by and among Leonite Fund I, LP (the “ Investor ”),

Original reporting
Published Jun 11, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CDIX
Neutral
medium confidence
Mentioned
$CDIX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDIXNeutralMed
01

Why it matters

The agreement creates an at-the-company’s-option pathway to issue common stock to the investor in tranches (fixed purchases) during an investment period, subject to conditions and a $0.20 minimum closing sale price for purchase direction.

02

Market read

This is a disclosed equity financing mechanism with a defined maximum commitment and a trading-price gate, which can drive dilution expectations and near-term trading volatility.

03

What to watch

Traders should monitor whether the $0.20 trading-price condition is met and how quickly fixed purchase notices are issued; actual dilution depends on executed settlements, not the maximum commitment.

Relevance 6/10Novelty 8/10Timing: Filed June 11, 2026 (8-K) with agreement dated June 5, 2026

Background

The 8-K reports entry into a Common Stock Purchase Agreement with Leonite Fund I, LP, including registration rights for resale of shares issued under the program.

Company-level read

Ticker impact

$CDIXNeutralMedium confidence
Context

CDIX entered a material definitive common stock purchase agreement allowing the company to sell up to $25M (expandable to $75M) to an investor.

Expected impact

Near-term volatility risk from dilution overhang; price sensitivity likely increases if the stock trades near the $0.20 threshold that governs purchases.

Evidence & confidence

This is a primary SEC 8-K disclosure of a financing structure, but the actual draw size/timing depends on future fixed purchase notices and satisfaction of conditions.

Market effects

Adds another microcap-style equity purchase agreement template, reinforcing dilution/financing risk premia in small-cap growth names.

Primarily US-listed microcap dynamics; limited cross-region spillover expected.

Low—this is company-specific financing mechanics with no stated global macro linkage.

Counterpoint

If the investor’s purchases are executed at favorable prices and the company uses proceeds efficiently, the agreement could reduce funding risk without immediate heavy dilution.

Key entities

  • Cardiff Lexington Corporation

    Nevada corporation issuing common stock under the purchase agreement.

  • Leonite Fund I, LP

    Investor purchasing shares under the fixed purchase mechanism.

  • Registration Rights Agreement

    Provides registration rights for resale of shares issued under the purchase agreement.

Related articles

$CDIXHighAI 8/10

CARDIFF LEXINGTON CORPORATION ANNOUNCES LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING MUSCULOSKELETAL HEALTHCARE PLATFORM

Cardiff Lexington Corp (CDIX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CARDIFF LEXINGTON CORPORATION ANNOUNCES LETTER OF INTENT FOR PROPOSED ACQUISITION OF LEADING MUSCULOSKELETAL HEALTHCARE PLATFORM Proposed Combination Would Significantly Expand Cardiff Lexington’s Musculoskeletal and Ancillary Healthcare Operations LEXINGTON, KY. — S

$CDIXMed

Cardiff Lexington Corporation: Cardiff Lexington Announces Second Quarter 2026 Financial Results

Cardiff Lexington Corporation (OTCQX:CDIX) filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 revenue of $2.16M versus $2.79M in 2025, and a net loss of $2.48M. For six months, revenue fell to $4.38M and net loss was $5.57M. It cited working capital constraints and plans to evaluate debt restructuring and equity infusions.

$LCIDHighAI 8/10

Lucid shares rise 10% as Saudi funding boost eases cash concerns

Lucid Group (LCID) shares rose 10% to $3.96 after securing a $1.75 billion credit line expansion from Saudi Arabia's Public Investment Fund, boosting liquidity to $3.75 billion. Q3 revenue was $350.3 million, missing estimates, with an adjusted loss of $2.30 per share. Free cash flow consumption fell 30% sequentially to $1.04 billion.